YOKNEAM, Israel, May 17, 2023 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, today announced that InMode will participate at the following investor conferences and events:
BNPP Exane Aesthetics Day
Presenters: Moshe Mizrahy, Chief Executive Officer, Yair Malca, Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer
Format: Virtual fireside chat moderated by Navann Ty, Lead Equity Analyst
When: Tuesday, May 23 at 10:00 am ET
A replay of webcast of the presentation can be accessed here.
Barclays West Coast Bus Trip
Presenters: Yair Malca, Chief Financial Officer and Spero Theodorou MD, Chief Medical Officer
Format: In-person investor bus tour at InMode's North American headquarters
Location: Irvine, CA
When: Tuesday, May 23 at 10:30 am PT
Jefferies Healthcare Conference
Presenters: Yair Malca, Chief Financial Officer
Format: In-person fireside chat moderated by Matt Taylor, Equity Analyst and one-on-one meetings
Location: NYC, NY
When: Wednesday, June 7 at 1:00 pm ET
A live webcast of the presentation can be accessed here.
About InMode
InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally-invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.
Investor Relations Contact:
Miri Segal-Scharia
MS-IR LLC
This email address is being protected from spambots. You need JavaScript enabled to view it.
917-607-8654
| Last Trade: | US$13.89 |
| Daily Change: | -0.21 -1.49 |
| Daily Volume: | 1,226,524 |
| Market Cap: | US$846.180M |
April 28, 2025 March 03, 2025 February 04, 2025 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
